Optimeos Life Sciences raised $1 million to advance its non-viral nanoparticle gene therapy for the treatment of Citrullinemia Type 1, a rare urea cycle disorder.
Optimeos Life Sciences raised $1 million to advance its non-viral nanoparticle gene therapy for the treatment of Citrullinemia Type 1, a rare urea cycle disorder.